-
7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%
Wednesday, September 28, 2022 - 12:10pm | 768Read More...Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...
-
4 Analysts Takeaways From Johnson & Johnson's Quarterly Results: What Investors Need To Know
Wednesday, July 20, 2022 - 12:02pm | 406Read More...Johnson & Johnson (NYSE: JNJ) reported a 3% growth in net sales to $24.02 billion, surpassing the consensus estimate of $23.81 billion, and a 4.4% growth in adjusted earnings to $2.59 per share, beating Street expectations of $2.57 per share. Raymond James On Johnson & Johnson: Analyst...
-
Johnson & Johnson Shares Might Break Lower Before They Break Out
Friday, July 21, 2017 - 9:53am | 474Read More...Just a day after Credit Suisse reinstated an Outperform rating on Johnson & Johnson (NYSE: JNJ) based on future gain from Actelion, BTIG and Atlantic Equities downgraded the stock from Neutral to Sell and Underweight, respectively, for nearly the opposite reason. Atlantic Equities: Weak Setup...
-
Biogen No Longer 'Too Risky,' Atlantic Analyst Sees Massive Upside
Friday, December 18, 2015 - 10:13am | 335Read More...Biogen Inc (NASDAQ: BIIB) shares have been on a downtrend since March 20, and are down 13 percent year-to-date. Atlantic Equities’ Steve Chesney initiated coverage of the company with an Overweight rating and a price target of $344. With multiple pipeline opportunities moving to...
